Safety and tolerability of switching to asenapine from other antipsychotic agents: Pooled results from two randomized multicenter trials in stable patients with persistent negative symptoms in schizophrenia

Neuropsychiatric Disease and Treatment

Volumn 8, Issue , 2012, Pages 247-257

  Cazorla, Pilar ^a   Mackle, Mary ^a   Zhao, Jun ^a   Ha, Xianwei ^a   Szegedi, Armin ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antipsychotics; Asenapine; Monotherapy; Olanzapine; Schizophrenia; Switch

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; BENPERIDOL; CHLORPROMAZINE; CHLORPROTHIXENE; CLOTIAPINE; CLOZAPINE; CYAMEMAZINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; LOXAPINE; MELPERONE; OLANZAPINE; PALIPERIDONE; PIMOZIDE; PIPOTIAZINE; PLACEBO; PROMETHAZINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; SULPIRIDE; THIORIDAZINE; TIAPRIDE; TRIFLUOPERAZINE; ZIPRASIDONE; ZOTEPINE;

ADULT; AGED; AGITATION; AKATHISIA; ANXIETY; APPETITE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ACTIVITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; FATIGUE; FEMALE; HUMAN; HYPESTHESIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MOUTH DISEASE; MULTICENTER STUDY; NAUSEA; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; POSITIVE SYNDROME; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEDATION; SIDE EFFECT; SOMNOLENCE; SUICIDE; TREATMENT DURATION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

EID: 84930485789     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S29891     Document Type: Article

References (14)

1. Lee CT, Conde BJ, Mazlan M, et al. Switching to olanzapine from previous antipsychotics: a regional collaborative multicenter trial assessing 2 switching techniques in Asia Pacifc. J Clin Psychiatry. 2002;63(7):569-576.
2. Lieberman JA, Stroup TS, McEvoy J P, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223.
3. Masand PS, Berry SL. Switching antipsychotic therapies. Ann Pharmacother. 2000;34(2):200-207.
4. Nyhuis AW, Faries DE, Ascher-Svanum H, Stauffer VL, Kinon BJ. Predictors of switching antipsychotic medications in the treatment of schizophrenia. BMC Psychiatry. 2010;10:75.
5. Weiden PJ, Young AH, Buckley P F. The art and science of switching of antipsychotic medications, part 1. J Clin Psychiatry. 2006;67(11):e15.
6. Weiden PJ. Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial. J Clin Psychiatry. 2007;68 Suppl 1:12-19.
7. Golebiewski K. Antipsychotic switching: when, how, why? Graylands Hospital Drug Bulletin. 2006;14(1):1-4.
8. Schering-Plough. Efficacy and safety of asenapine compared with olanzapine in patients with persistent negative symptoms of schizophrenia (A7501013) (COMPLETED) (P05771). In: ClinicalTrials. gov. Bethseda, MD: US National Library of Medicine; 2010 [updated April 8, 2010]. Available from: http://clinicaltrials.gov/ct2/ show/NCT00145496. NLM identifier: NCT00145496. Accessed April 19, 2012.
9. Schering-Plough. Effcacy and safety of asenapine compared with olanzapine in patients with persistent negative symptoms of schizophrenia (25543) (COMPLETED) (P05817). In: ClinicalTrials.gov. Bethseda, MD: US National Library of Medicine; 2010 [updated October 2, 2009]. Available from: http://clinicaltrials.gov/ct2/ show/NCT00212836. NLM identifier: NCT00212836. Accessed April 19, 2012.
10. Buchanan R, Panagides J, Kouassi A, Szegedi A. Asenapine versus olanzapine in patients with predominent persistent negative symptoms of schizophrenia. Schizophrenia Research. 2008;102(2):252.
11. Hester EK, Thrower MR. Current options in the management of olanzapine-associated weight gain. Ann Pharmacother. 2005;39(2): 302-310.
12. Mukundan A, Faulkner G, Cohn T, Remington G. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst Rev. 2010;12:CD006629.
13. Newcomer J W. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry. 2007;68 Suppl 4:8-13.
14. US Food and Drug Administration. FDA drug safety communication: serious allergic reactions reported with the use of Saphris (asenapine maleate). Rockville, MD: US Food and Drug Administration; 2011. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm270243. htm#sa. Accessed January 29, 2012.